Genflow advances SIRT6 gene therapy

Genflow Biosciences Plc

Genflow Biosciences has strengthened the development case for its SIRT6 gene therapy platform after its Sarcopenia and Longevity in Aged Beagles clinical trial met its primary endpoint, providing new evidence that the company’s technology can influence biological markers associated with ageing.

The SLAB study evaluated Genflow’s centenarian SIRT6 therapy in beagles aged over 10. Treated animals recorded a reduction in biological age compared with untreated controls, measured using the GRIM DNA methylation clock.

The result gives Genflow an additional proof point for a development strategy centred on SIRT6, a gene involved in cellular processes associated with ageing. The company is focused on a specific variant found more frequently in centenarians than in the wider population, with its lead compound GF-1002 designed to deliver this variant directly.

The trial was randomised and blinded and included 24 aged beagles divided into four groups. Two groups received different doses of naked DNA treatment, another received a single dose delivered through an AAV8 viral vector, while the fourth acted as a saline control.

Meeting the primary endpoint follows earlier indications from the programme. Genflow had previously reported positive interim muscle data in February, followed by evidence of sustained safety and efficacy at a three-month follow-up in April. The company has also said treated animals improved across several secondary functional and observable measures, although the detailed results have not yet been released.

Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Genflow Biosciences reports positive gene therapy results in older dogs

Genflow Biosciences reported that its GF-1002 gene therapy reduced biological age measurements in older dogs, meeting the primary objective...

Genflow Biosciences reports early findings from SIRT6 gene therapy study

Genflow Biosciences reports early findings from its SIRT6 gene therapy study in older dogs, with further monitoring planned over...

Genflow Biosciences targets canine longevity as interest in pet ageing treatments grows

Genflow Biosciences is developing SIRT6 gene therapy aimed at improving canine longevity and reducing age-related muscle loss, as interest...

Biotech companies target longer lifespans for dogs and cats through gene therapy

Biotechnology companies are developing gene therapies and anti-ageing drugs for dogs and cats, targeting age-related diseases and the potential...

Genflow Biosciences in focus as longevity research expands into animal health

Longevity research is expanding into animal health, while Genflow Biosciences continues to focus on the potential of SIRT6-related science...

Pet food industry turns to healthy ageing as demand for longevity products grows

Growing interest in pet longevity is creating opportunities for specialised nutrition, supplements and veterinary treatments. Improved research into the...

Search